查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1701384

美國獸醫癌症診斷市場規模、佔有率、趨勢分析報告（按動物類型、檢測類型、癌症類型、最終用途、國家/地區、細分市場預測），2025 年至 2030 年

U.S. Veterinary Oncology Diagnostics Market Size, Share & Trends Analysis Report By Animal Type (Canine, Feline), By Test Type (Biopsy, Genome Testing), By Cancer Type (Skin Cancers, Sarcomas), By End Use, By Country, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國獸醫癌症診斷市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，美國獸醫癌症診斷市場預計到 2030 年將達到 16 億美元，2025 年至 2030 年的複合年成長率為 8.55%。

市場的主要促進因素包括動物數量和圈養率的上升、動物支出的增加、對預防性動物保健的日益關注，以及主要企業之間為擴大產品供應而不斷加強的夥伴關係。例如，2025 年 2 月，Torigen Pharmaceuticals 和 Proscia 合作利用人工智慧數位病理學更快、更準確地診斷寵物的癌症。這可以實現更快、更個人化的免疫治療，並提高轉移性血管肉瘤犬的存活率。 Torigen 的人工智慧診斷將顯著提高癌症檢測的準確性和速度。 3-5 天內提供結果可縮短診斷週轉時間，使獸醫能夠更快地開始標靶治療。這項技術創新預計將推動獸醫腫瘤學對數位病理解決方案的需求，從而促進市場成長。

此外，獸醫癌症診斷測試​​的進步以及動物健康診斷研發投資的增加以推出創新產品正在推動市場成長。例如，2024年12月，Pet Preferred Diagnostics宣布推出一項針對貓狗的突破性早期癌症診斷測試​​，可檢測與21種腫瘤和14種神經系統疾病相關的11種特異性腫瘤抗體。這種高度敏感的血清學檢測通常能夠在臨床症狀出現之前發現惡性腫瘤，從而實現早期治療。該測試是獸醫學中唯一能夠區分多種腫瘤和神經系統疾病的測試，並且是非侵入性的、價格實惠的，並且可以在 24 小時內提供快速解決方案並得出結果。

寵物癌症發生率的上升是美國獸醫癌症診斷市場的主要驅動力，每年有四分之一的狗和五分之一的貓被診斷出罹患癌症。隨著飼主尋求早期發現和個人化治療，寵物擁有的增加和人性化趨勢正在推動對先進診斷的需求。液態切片測試（例如 PetDx 的 OncoK9）和人工智慧數位病理測試（例如 Torigen 與 Proscia 的合作）等技術進步正在提高診斷的準確性和效率。此外，價格實惠的家庭癌症篩檢測試（如 Oncotect）的普及使得早期診斷更加容易，從而進一步促進了市場的成長。

美國獸醫癌症診斷市場報告重點

  • 根據測試類型，切片檢查部分佔據市場主導地位，2024 年的佔有率為 28.75%。然而，由於獸醫癌症診斷檢測套組的技術進步，基因組測試部分預計將以最快的速度成長，預測期內的複合年成長率為 9.62%。
  • 根據動物類型，預計狗類將在 2024 年佔據最大的收益佔有率，這是由於狗的癌症數量不斷增加，並且有大量用於狗癌症診斷的產品可供選擇。由於全球貓科動物數量的增加以及相關疾病的顯著增加，預計 2025 年至 2030 年間貓科動物市場將以最快的速度成長。
  • 根據癌症類型，皮膚癌部分預計將在 2024 年佔據最高收益佔有率，並以 8.71% 的最快複合年成長率成長，這歸因於狗和貓鱗狀細胞癌和皮膚腫瘤患病率的上升。
  • 根據最終用途，由於醫院對診斷的需求不斷增加以及易於獲得的先進動物癌症診斷技術，獸醫醫院和診所部門預計將在 2024 年佔據市場的最高收入佔有率。預計未來幾年該領域將以最快的複合年成長率成長。
  • 隨著創新液態切片和先進的多癌症診斷技術的發展，獸醫癌症診斷檢測套組變得更加準確、易於使用和具有成本效益。預計這些進步將推動市場成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國獸醫癌症診斷市場的趨勢與展望

  • 市場展望
    • 母市場
    • 附隨市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國獸醫癌症診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 法律規範
    • 以主要類型估算的動物數量（2018-2024 年）
    • COVID-19影響分析

第4章美國獸醫癌症診斷市場：按動物類型進行的估計和趨勢分析

  • 細分儀表板
  • 美國獸醫癌症診斷市場動物類型差異分析
  • 2018-2030年美國獸醫癌症診斷市場規模及趨勢分析（依動物類型）
    • 狗
    • 貓
    • 其他

第5章美國獸醫癌症診斷市場：按測試類型進行的估計和趨勢分析

  • 細分儀表板
  • 美國獸醫癌症診斷市場測試類型變化分析
  • 2018-2030 年美國獸醫癌症診斷市場規模及趨勢分析（依檢測類型）
    • 血液檢查
    • 切片檢查
    • 基因組檢測
    • 內視鏡檢查
    • 尿液檢查
    • 影像學診斷

第6章美國獸醫癌症診斷市場：按癌症類型進行的估計和趨勢分析

  • 細分儀表板
  • 美國獸醫癌症診斷市場按癌症類型變化分析
  • 美國獸醫癌症診斷市場規模和趨勢分析（按癌症類型，2018-2030 年）
    • 淋巴瘤
    • 肉瘤
    • 乳腺腫瘤
    • 皮膚癌
    • 其他

第7章美國獸醫癌症診斷市場：按最終用途的估計和趨勢分析

  • 細分儀表板
  • 美國獸醫癌症診斷市場最終用途趨勢分析
  • 2018-2030 年美國獸醫癌症診斷市場規模及趨勢分析（依最終用途）
    • 參考實驗室
    • 獸醫診所和診所

第8章競爭格局

  • 市場參與企業分類
  • 參與企業概況
  • 財務表現
  • 產品基準
  • 2024年市場分析（熱圖分析）
  • 戰略地圖
    • 合併與收購
    • 發射
    • 夥伴關係和合作
    • 擴張
    • 其他
  • 公司簡介
    • Zoetis
    • Antech Diagnostics, Inc.（Mars Inc.）
    • IDEXX Laboratories, Inc.
    • Neogen Corporation
    • Gold Standard Diagnostics（Eurofins Technologies）
    • Embark Veterinary, Inc.
    • VolitionRx Limited
    • CANCAN DIAGNOSTICS
    • Oncotect
    • PetDx
Product Code: GVR-4-68040-541-6

U.S. Veterinary Oncology Diagnostics Market Growth & Trends:

The U.S. veterinary oncology diagnostics market size is expected to reach USD 1.60 billion by 2030, registering a CAGR of 8.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, an increasing focus on preventative animal healthcare, and growing partnerships among key players to expand product offerings. For instance, in February 2025, Torigen Pharmaceuticals and Proscia partnered to leverage AI-enabled digital pathology for faster, more accurate cancer diagnoses in pets. This enables quicker, personalized immunotherapy treatments, enhancing survival rates for dogs with metastatic hemangiosarcoma. Torigen's AI-powered diagnostics significantly enhance the accuracy and speed of cancer detection. By delivering results within 3-5 days, it reduces diagnostic turnaround time, allowing veterinarians to begin targeted treatments sooner. This innovation is expected to boost market growth by driving demand for digital pathology solutions in veterinary oncology.

Additionally, advances in veterinary cancer diagnostic testing, and rising R&D investment in animal health diagnostics to launch innovative products are fueling market growth. For instance, in December 2024, Pet Preferred Diagnostics introduced a groundbreaking early cancer diagnostic test for dogs and cats that detects 11 specific onconeural antibodies linked to 21 types of tumors and 14 neurological diseases. This highly sensitive serological test can identify malignancy, often before clinical signs appear, enabling early treatment. It is the only test available in veterinary medicine that differentiates various tumors and neurological conditions, offering a non-invasive, affordable, and quick solution with a 24-hour turnaround.

The rising prevalence of cancer in pets is a key driver of the U.S. veterinary oncology diagnostics market, with 1 in 4 dogs and 1 in 5 cats diagnosed with cancer annually. Increasing pet ownership and humanization trends have boosted demand for advanced diagnostics as pet owners seek early detection and personalized treatments. Technological advancements, such as liquid biopsy tests (e.g., OncoK9 by PetDx) and AI-powered digital pathology (e.g., Torigen and Proscia partnership), are enhancing diagnostic accuracy and efficiency. Additionally, the growing availability of affordable, at-home cancer screening tests (e.g., Oncotect) is making early diagnosis more accessible, further propelling market growth.

U.S. Veterinary Oncology Diagnostics Market Report Highlights:

  • Based on test type, the biopsy segment dominated the market with a share of 28.75% in 2024. However, the genome testing segment is expected to grow at the fastest CAGR of 9.62% during the forecast period due to technological advancements in veterinary cancer diagnostic test kits.
  • Based of animal type, the canine segment attributed to the largest revenue share in 2024 due to the increase in the dog cancer population and the availability of a huge number of products for canine cancer diagnosis. The feline segment is projected to grow at the fastest rate from 2025 to 2030, owing to the rising population of cats worldwide and the apparent rise in the number of associated diseases.
  • Based on cancer type, the skin cancers segment accounted for the highest revenue share in 2024 and is expected to grow at the fastest CAGR of 8.71% owing to the rising prevalence of squamous cell carcinoma and skin tumors in cats and dogs.
  • Based on end use, the veterinary hospitals and clinics segment held the highest revenue share of the market in 2024 owing to the increasing demand for diagnostics and readily accessible advanced veterinary cancer diagnostic technologies in hospitals. This segment is estimated to grow at the fastest CAGR in the coming years.
  • Advances in innovative liquid biopsy and advanced multi-cancer diagnostic technology have led to the development of more accurate, user-friendly, and cost-effective veterinary oncology diagnostic test kits. Such advancements are expected to drive market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Oncology Diagnostics Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of cancer in pets
      • 3.2.1.2. Increasing R&D in veterinary oncolgy diagnostics
      • 3.2.1.3. Growing focus on animal safety
      • 3.2.1.4. Growing uptake of pet insurance
      • 3.2.1.5. Technological advancements in early pet cancer diagnosis
      • 3.2.1.6. Increase in pet population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of veterinary oncology diagnostics
      • 3.2.2.2. Lack of awareness in developing countries
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Oncology Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental Landscape
    • 3.3.3. Regulatory Framework
    • 3.3.4. Estimated Animal Population, by Key Species, 2018 - 2024
    • 3.3.5. COVID-19 Impact Analysis

Chapter 4. U.S. Veterinary Oncology Diagnostics Market: Animal Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Oncology Diagnostics Market Animal Type Movement Analysis
  • 4.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Animal Type, 2018 - 2030 (USD Million)
    • 4.3.1. Canine
      • 4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.2. Feline
      • 4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.3.3. Others
      • 4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Veterinary Oncology Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Oncology Diagnostics Market Test Type Movement Analysis
  • 5.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Test Type 2018 - 2030 (USD Million)
    • 5.3.1. Blood Tests
      • 5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.2. Biopsy
      • 5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3. Genome testing
      • 5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.4. Endoscopy
      • 5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.5. Urinalysis
      • 5.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.6. Imaging
      • 5.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Veterinary Oncology Diagnostics Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Oncology Diagnostics Market Cancer Type Movement Analysis
  • 6.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Cancer Type, 2018 - 2030 (USD Million)
    • 6.3.1. Lymphoma
      • 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Sarcomas
      • 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mammary Gland Tumors
      • 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Skin Cancers
      • 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.5. Others
      • 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Veterinary Oncology Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Oncology Diagnostics Market End-Use Movement Analysis
  • 7.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By End-Use 2018 - 2030 (USD Million)
    • 7.3.1. Reference Laboratories
      • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Veterinary hospitals and clinics
      • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Participants Overview
  • 8.3. Financial Performance
  • 8.4. Product Benchmarking
  • 8.5. Market Position Analysis, 2024 (Heat Map Analysis)
  • 8.6. Strategy Mapping
    • 8.6.1. Mergers and Acquisitions
    • 8.6.2. Launch
    • 8.6.3. Partnerships & Collaborations
    • 8.6.4. Expansion
    • 8.6.5. Others
  • 8.7. Company Profiles
    • 8.7.1. Zoetis
      • 8.7.1.1. Participant's overview
      • 8.7.1.2. Financial performance
      • 8.7.1.3. Product Benchmarking
      • 8.7.1.4. Strategic initiatives
    • 8.7.2. Antech Diagnostics, Inc. (Mars Inc.)
      • 8.7.2.1. Participant's overview
      • 8.7.2.2. Financial performance
      • 8.7.2.3. Product Benchmarking
      • 8.7.2.4. Strategic initiatives
    • 8.7.3. IDEXX Laboratories, Inc.
      • 8.7.3.1. Participant's overview
      • 8.7.3.2. Financial performance
      • 8.7.3.3. Product Benchmarking
      • 8.7.3.4. Strategic initiatives
    • 8.7.4. Neogen Corporation
      • 8.7.4.1. Participant's overview
      • 8.7.4.2. Financial performance
      • 8.7.4.3. Product Benchmarking
      • 8.7.4.4. Strategic initiatives
    • 8.7.5. Gold Standard Diagnostics (Eurofins Technologies)
      • 8.7.5.1. Participant's overview
      • 8.7.5.2. Financial performance
      • 8.7.5.3. Product Benchmarking
      • 8.7.5.4. Strategic initiatives
    • 8.7.6. Embark Veterinary, Inc.
      • 8.7.6.1. Participant's overview
      • 8.7.6.2. Financial performance
      • 8.7.6.3. Product Benchmarking
      • 8.7.6.4. Strategic initiatives
    • 8.7.7. VolitionRx Limited
      • 8.7.7.1. Participant's overview
      • 8.7.7.2. Financial performance
      • 8.7.7.3. Product Benchmarking
      • 8.7.7.4. Strategic initiatives
    • 8.7.8. CANCAN DIAGNOSTICS
      • 8.7.8.1. Participant's overview
      • 8.7.8.2. Financial performance
      • 8.7.8.3. Product Benchmarking
      • 8.7.8.4. Strategic initiatives
    • 8.7.9. Oncotect
      • 8.7.9.1. Participant's overview
      • 8.7.9.2. Financial performance
      • 8.7.9.3. Product Benchmarking
      • 8.7.9.4. Strategic initiatives
    • 8.7.10. PetDx
      • 8.7.10.1. Participant's overview
      • 8.7.10.2. Financial performance
      • 8.7.10.3. Product Benchmarking
      • 8.7.10.4. Strategic initiatives

List of Tables

  • Table. 1 List of Secondary Sources
  • Table. 2 List of Abbreviations
  • Table. 3 U.S. veterinary oncology diagnostics market, by Animal, 2018 - 2030 (USD Million)
  • Table. 4 U.S. veterinary oncology diagnostics market, by Test Type, 2018 - 2030 (USD Million)
  • Table. 5 U.S. veterinary oncology diagnostics market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table. 6 U.S. veterinary oncology diagnostics market, by End-Use, 2018 - 2030 (USD Million)
  • Table. 7 Company Overview
  • Table. 8 Service Benchmarking
  • Table. 9 Financial Performance
  • Table. 10 Strategic Initiatives

List of Figures

  • Fig. 1 U.S. veterinary oncology diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for a commodity flow analysis of U.S. veterinary oncology diagnostics market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2024 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2024
  • Fig. 17 U.S. veterinary oncology diagnostics market Dynamics
  • Fig. 18 Estimated animal population, 2018 - 2024 by key species
  • Fig. 19 U.S. veterinary oncology diagnostics market: PORTER's analysis
  • Fig. 20 U.S. veterinary oncology diagnostics market: PESTEL analysis
  • Fig. 21 U.S. veterinary oncology diagnostics market by Animal: Key Takeaways
  • Fig. 22 U.S. veterinary oncology diagnostics market by Animal, 2024 & 2030
  • Fig. 23 Canine market, 2018 - 2030 (USD Million)
  • Fig. 24 Feline market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. veterinary oncology diagnostics market by Test Type: Key Takeaways
  • Fig. 27 U.S. veterinary oncology diagnostics market by Test Type, Market Share, 2024 & 2030
  • Fig. 28 Blood Tests market, 2018 - 2030 (USD Million)
  • Fig. 29 Biopsy market, 2018 - 2030 (USD Million)
  • Fig. 30 Genome testing market, 2018 - 2030 (USD Million)
  • Fig. 31 Endoscopy market, 2018 - 2030 (USD Million)
  • Fig. 32 Urinalysis market, 2018 - 2030 (USD Million)
  • Fig. 33 Imaging market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. veterinary oncology diagnostics market by Cancer Type: Key Takeaways
  • Fig. 35 U.S. veterinary oncology diagnostics market by Cancer Type, Market Share, 2024 & 2030
  • Fig. 36 Lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 37 Sarcomas market, 2018 - 2030 (USD Million)
  • Fig. 38 Mammary Gland Tumors market, 2018 - 2030 (USD Million)
  • Fig. 39 Skin Cancers market, 2018 - 2030 (USD Million)
  • Fig. 40 Others market, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. veterinary oncology diagnostics market by End-Use: Key Takeaways
  • Fig. 42 U.S. veterinary oncology diagnostics market by End-Use, Market Share, 2024 & 2030
  • Fig. 43 Reference Laboratories market, 2018 - 2030 (USD Million)
  • Fig. 44 Veterinary hospitals and clinics market, 2018 - 2030 (USD Million)
  • Fig. 45 Market Participant Categorization
  • Fig. 46 Heat map analysis
  • Fig. 47 Strategic Framework